Here’s what you should know:
1. SYN-010 is a proprietary, modified-release lovastatin lactone formulation used for constipation treatments.
2. The company will be able to protect SYN-010 until at least 2034, allowing for a period of extended commercialization.
3. Fifty-five U.S. and foreign patents protect SYN-010. There are another 25 patents pending.
Synthetic Biologics CEO Jeffrey Riley said in a release, “Once issued, this patent will extend the protection around the use of SYN-010 to treat IBS-C by an additional eleven years and significantly strengthens the opportunity to build long-term value for our shareholders.”
More articles on gastroenterology:
Analysts predict the uncertain future of Ironwood Pharmaceuticals — 4 insights
GI center to know: Gastroenterology Associates
GI leader to know: Dr. Steven Condron of Avera Medical Group
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
